December 11, 2020
1 min watch
Svoboda J, et al. Abstract 473. Presented at: ASH Annual Meeting and Exposition (virtual meeting); Dec. 5-8, 2020.
Svoboda reports consulting for Adaptive, AstraZeneca, Atara, BMS, Genmab, Imbrium, Pharmacyclics and Seattle Genetics; and receiving research funding from AstraZeneca, BMS, Incyte, Merck, Pharmacyclics, Seattle Genetics and TG.
The combination of everolimus and itacitinib, an oral JAK inhibitor, was well-tolerated in patients with relapsed or refractory Hodgkin lymphoma, according to data presented at ASH Annual Meeting and Exposition.
The JAK-STAT pathway appears to be altered in up to 80% of patients with newly diagnosed Hodgkin lymphoma, according to Jakub Svoboda, MD, of Penn Medicine.
This investigator initiated, phase 1/2 trial showed that this combination was fairly well-tolerated and had a favorable toxicity profile, Svoboda told Healio in a video interview.
“The responses are surprisingly high. Our overall response rate … was 75%, with two patients or 12.5% achieving complete response,” he said. “Some of these responses are ongoing for a year.”
For the future, Svoboda hopes studies like this will open up the door to enable mutation analyses from the circulating tumor DNA.
“That’s kind of the future of treatment for patients with these hematologic malignancies – that we will be able to figure out and tailor the specific treatment based not only on the diagnosis but also on the specific mutations and the altered pathways,” Svoboda said. “This is the type of study that may help to move the field in that way where specific pathways will be targeted.”